Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | -2.02% | -5.47% | -88.19% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Business Summary
Number of employees: 41
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Paul Eckburg
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-31 |
Jennifer Huber
LAW | General Counsel | - | - |
Josh Eizen
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 19-10-31 | |
Kevin Krause
PRN | Corporate Officer/Principal | 49 | 21-07-31 |
Sanjay Chanda
PRN | Corporate Officer/Principal | 59 | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Director/Board Member | 58 | 22-05-08 | |
Robin Readnour
BRD | Director/Board Member | 59 | 19-10-31 |
Stephanie Wong
BRD | Director/Board Member | 50 | 21-03-31 |
Kabeer Aziz
BRD | Director/Board Member | 34 | 19-10-31 |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Gilbert Marks
BRD | Director/Board Member | 66 | 20-01-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,829,040 | 22,321,237 ( 74.83 %) | 0 | 74.83 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.19% | 72.19M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ANTX Stock
- Company AN2 Therapeutics, Inc.